REFERENCES
Holmes B, Heel RC, Brogden RN, Speight TM, Avery GS: Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs 27:301–327, 1984
Dourakis SP, Tzemanakis E, Sinani C, Kafiri G, Hadziyannis SJ: Gliclazide-induced hepatitis. Eur J Gastroenterol Hepatol 12:119–121, 2000
Zimmerman HJ: Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, Lippincott Williams and Wilkins, 1999
Goodman RC, Dean PJ, Radparvar A, Kitabchi AE: Glyburide-induced hepatitis. Ann Intern Med 106:837–839, 1987
Wongpaitoon V, Mills PR, Russell RI, Patrick RS: Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy. Postgrad Med J 57:244–246, 1981
Tholakanahalli VN, Potti A, Heyworth MF: Glibenclamideinduced cholestasis. West J Med 168:274–277, 1998
Clarke BF, Campbell IW, Ewing DJ, Beveridge GW, Mac-Donald MK: Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy. Diabetes 23:739–742, 1974
Tzanakis N, Bouros D, Siafakas N: Eosinophilic pleural effusion due to gliclazide. Respir Med 94:94, 2000
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfelde KH, Zeniya M, et al: International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938, 1999
Poonawala A, Nair SP, Thuluvath PJ: Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case–control study. Hepatology 32:689–692, 2000
Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ: Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying liver disease. Hepatology 29:664–669, 1999
Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105:1067–1075, 2000
Desfaits AC, Serri O, Renier G: Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factoralpha production in NIDDM patients after gliclazide treatment. Diabetes Care 2:487–493, 1998
Coyle WJ, Delaney N, Yoshihashi A, Lawson P: Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTs and improves histology. Gastroenterology 116:A1198, 1999 (abstract)
King PD, Blitzer BL: Drug-induced cholestasis: pathogenesis and clinical features. Semin Liver Dis 10:316–321, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chitturi, S., Le, V., Kench, J. et al. CASE REPORT: Gliclazide-Induced Acute Hepatitis with Hypersensitivity Features. Dig Dis Sci 47, 1107–1110 (2002). https://doi.org/10.1023/A:1015002526879
Issue Date:
DOI: https://doi.org/10.1023/A:1015002526879